

# Sensitive detection of glucagon aggregation using amyloid fibril-specific antibodies

Samuel D. Stimple<sup>1,2</sup>, Sibel Kalyoncu<sup>4</sup>, Alec A. Desai<sup>2</sup>, Jesper E. Mogensen<sup>5</sup>, Lotte T. Spang<sup>5</sup>, De sir e J. Asgreen<sup>5</sup>, Arne Staby<sup>5</sup>, Peter M. Tessier<sup>1,2,3</sup>

<sup>1</sup>Departments of Pharmaceutical Sciences, <sup>2</sup>Chemical Engineering, and <sup>3</sup>Biomedical Engineering, Biointerfaces Institute, University of Michigan, Ann Arbor, MI 48109, USA

<sup>4</sup>Izmir Biomedicine and Genome Center, Dokuz Eyl l University, Bal ova, Izmir, Turkey

<sup>5</sup>Novo Nordisk A/S, Novo Alle 1,DK-2880 Bagsv rd, Denmark

Sensitive detection of protein aggregates is important for evaluating the quality of biopharmaceuticals and diagnosing various neurodegenerative diseases. However, it is challenging to detect extremely low concentrations of aggregated protein in the presence of high concentrations of natively-folded (soluble) protein. Glucagon, a peptide hormone used in the treatment of extreme hypoglycemia, is aggregation-prone and forms amyloid fibrils. Detection of glucagon fibrils using conformation-specific antibodies is an attractive approach for identifying such aggregates during process and formulation development. Therefore, we have used yeast surface display and magnetic-activated cell sorting to sort single-chain antibody libraries to identify antibody variants with high conformational specificity for glucagon fibrils. Notably, we find several high-affinity antibodies that display excellent selectivity for glucagon fibrils. Moreover, the sensitivity of our assay – which involves direct (non-antibody mediated) glucagon immobilization in microtiter plates – can be significantly enhanced by pretreating the plates with various types of globular proteins. Increased concentrations of glucagon also significantly improve the sensitivity of our assay, which appears to be due to the strong seeding activity of immobilized fibrils at high glucagon concentrations. Our final assay is approximately two orders of magnitude more sensitive than detection using conventional, amyloid-specific fluorescent dyes (Thioflavin T). We expect that this type of sensitive immunoassay can be readily integrated into the drug development process to improve the generation of safe and effective peptide therapeutics.

---

To whom correspondence should be addressed: Email: ptessier@umich.edu

Running title: Glucagon fibril immunoassay

Key words: conformation; aggregate; antibody fragment; directed evolution; ELISA.

## 1. INTRODUCTION

There is wide-spread interest in using biologics – ranging from relatively small peptide hormones to large monoclonal antibodies – as drugs given their unique properties, including their high affinity and specificity for their targets and low toxicity and immunogenicity. In the area of polypeptide therapeutics, the glucose-regulated peptide glucagon has proven to be a valuable therapeutic agent that modulates blood glucose levels. Glucagon is produced through the tissue-specific post-translational processing of preproglucagon (White and Saunders 1986). Glucagon is a first-line treatment in addressing extreme hypoglycemia, among other indications (Hall-Boyer et al. 1984). It stimulates glycogenolysis and gluconeogenesis via binding to the glucagon receptor, resulting in a signal cascade that rapidly increases blood sugar levels (Unson 2002). The important biological role of this peptide has motivated interest in using it for the treatment of extreme hypoglycemia in the clinic, and has made glucagon a molecule of interest (alongside insulin) for development of bihormonal pumps that manage blood sugar levels in individuals with Type 1 diabetes (Castle et al. 2010; El-Khatib et al. 2010; Russell et al. 2012; Russell et al. 2014; Steiner et al. 2010)

A key challenge in developing biologics as therapeutics is that they display variable and difficult-to-predict levels of aggregation (Dobson 1999), which can lead to the presence of aggregated species in the purified and formulated drug product (Onoue et al. 2004; Wang 2005). For highly aggregation-prone biologics, concerns regarding batch-to-batch variability in drug quality and immunogenicity can greatly complicate the downstream stages of bioprocess development and quality assurance, while also presenting threats to patient safety. Indeed, native glucagon is well-known for displaying poor solubility and high propensity for aggregation into amyloid fibrils of diverse morphologies (De Jong et al. 2006; Dong et al. 2006; Ghodke et al. 2012; Gratzer et al. 1967; Pedersen 2010; Pedersen et al. 2006; Pedersen and Otzen 2008). For instance, glucagon fibrillation can occur rapidly, and its rate is highly dependent on the initial concentration of amyloid present in the sample. Consequently, reconstituted glucagon is generally only stable over short timeframes and must be solubilized immediately before use. Such challenges have led to significant efforts in optimization of formulations to minimize aggregation (Bakhtiani et al. 2015; Pohl et al. 2015; Steiner et al. 2010; Ward et al. 2010), enhancement of peptide stability and solubility through alterations to amino acid or chemical composition (Chabenne et al. 2010), and development of assays that detect aggregates (or the propensity to form aggregates) using fluorescent dyes, intrinsic tryptophan fluorescence, and other techniques (Hovgaard et al. 2007; Oliveira et al. 2009; Pedersen et al. 2006). Many of these approaches have proven successful in preliminary and early clinical studies.

Despite this important progress, it remains extremely challenging to sensitively detect endogenous glucagon aggregates that are present at extremely low levels (*e.g.*, <10 ppm). Such concentrations are typically too dilute for detection using conventional methods such as amyloid-specific dyes (*e.g.*, Thioflavin T, ThT) and size-exclusion chromatography without first stressing the samples to amplify the amount of aggregate. We reasoned that an ELISA-based method could be developed to achieve much more rapid and sensitive detection of glucagon amyloid fibrils than conventional methods without the need for stressing the samples to amplify aggregate content.

Due to the lack of existing conformational antibodies specific for glucagon, we sought to generate such antibodies using *in vitro* antibody discovery methods that involve sorting single-chain antibody fragment (scFv) libraries using yeast surface display for strong recognition of aggregated glucagon and minimal recognition of soluble glucagon. Herein, we report the identification of amyloid-specific antibodies that recognize glucagon fibrils and demonstrate an ELISA method that is approximately two orders of magnitude more sensitive than conventional methods.

## **2. MATERIALS AND METHODS**

### **2.1 Preparation of soluble and fibrillated glucagon**

Glucagon powder (Novo Nordisk A/S) was solubilized at a concentration of 10 g/L in 10 mM HCl and sterilized by filtration through a 0.22  $\mu$ M filter. Glucagon was then diluted to a final concentration of 1 g/L (50 mM glycine, pH 2.5). Fibrils were assembled at 37 °C with shaking (900 rpm, 18 h), and then recovered by ultracentrifugation at 221,000xg for 1 h at 4 °C (Tube PC Thickwall, 1 mL, 45237, Thermo Fisher Scientific). Fibril pellets were washed once and then resuspended in the original volume of buffer (50 mM glycine, pH 2.5) for ELISA analysis or PBS for coupling to magnetic beads, sorting, and initial ELISA screening. Fibril concentrations were determined by BCA or micro-BCA assay (23225 or 23235, Thermo Fisher Scientific). Before use, fibrils were sonicated (FB-120 Sonic Dismembrator, Thermo Fisher Scientific) on ice for 30 s at 100% amplitude (3 cycles of 10 s on and 30 s off).

### **2.2 Fluorescence analysis of glucagon fibrils**

Soluble and fibrillar glucagon were separately diluted to a final concentration of 245  $\mu$ M (50 mM glycine, pH 2.5). For tryptophan fluorescence emission scans, 50  $\mu$ L of sample was added to the wells of a black 384-well plate (12566624, Thermo Fisher Scientific), and intrinsic fluorescence emission scans were performed from 300 to 500 nm ( $\lambda_{ex}$  = 280 nm). For ThT fluorescence emission scans, ThT was added to the samples to a final concentration of 4  $\mu$ M (final glucagon concentration of 200  $\mu$ M). A 50  $\mu$ L sample of the peptide/ThT mixtures was added to the wells of black 384-well plates, and fluorescence emission scans were performed from 450 to 550 nm ( $\lambda_{ex}$  = 444 nm). All fluorescence readings were performed at room temperature in a BioTek Synergy Neo microplate-reader.

### **2.3 Atomic force microscopy**

Glucagon fibrils were diluted to a concentration of 50  $\mu$ M in 50 mM glycine (pH 2.5). A 10  $\mu$ L sample of glucagon fibrils was deposited on a 1cm x 1cm sheet of Muscovite Mica (V-1 Quality, 71855-05, Electron Microscopy Sciences) that was attached to a glass slide with double-sided tape. The sample was incubated on the mica for 45 min, washed with 1 mL of sterile deionized water, and imaged at room temperature using an Asylum Research Molecular Force Probe 3D. Tapping-mode (non-contact) imaging in air was used to determine the

morphology of the fibrils. Image processing and analysis of the force data were carried out using the built-in features of MFP 3D software.

## 2.4 Cloning of antibody variants

Single-chain variable fragments (scFvs) specific for glucagon fibrils were isolated using yeast surface display and magnetic sorting using Dynabeads (Dynabeads M-280 Tosylactivated, 14203, Invitrogen) coupled to fibrillar or soluble glucagon (for positive and negative selections, respectively). Briefly,  $8 \times 10^7$  beads were washed twice with 1 mL of PBS. Soluble glucagon (100  $\mu\text{g}$ ) was then coupled to the beads in 800  $\mu\text{L}$  of buffer (50 mM borate, pH 9.5) overnight (4 °C, no mixing). Fibrillar glucagon (100  $\mu\text{g}$ ) was coupled in 800  $\mu\text{L}$  of PBS overnight at room temperature with end-over-end mixing. The beads were quenched by washing twice with PBS supplemented with 10 mM glycine and then washed with PBS supplemented with 1 g/L BSA (PBS-B) before incubation with yeast. All positive selections were performed against fibrillar glucagon in PBS-B supplemented with 1 % milk, and negative selections were performed against soluble glucagon in PBS-B.

Following eight rounds of yeast sorting, the plasmid DNA for the enriched yeast libraries was recovered with the Zymoprep Yeast Plasmid Miniprep II Kit (D2004, Zymo Research). The isolated scFv genes were amplified with Phusion High-Fidelity DNA Polymerase (M0530L, New England Biolabs), and cloned by standard DNA restriction and ligation methods. The scFv genes were cloned between the *NcoI* and *NotI* restriction sites of anti-Notch1\_E6-pBIOCAM5, which was a gift from John McCafferty (Addgene plasmid # 39344) (Falk et al. 2012). The resulting constructs encoded a bivalent scFv-human Fc fusion protein containing C-terminal 6xHis and 3xFLAG tags, and their DNA sequences were determined by Sanger sequencing.

## 2.5 Antibody expression and purification

The antibodies were expressed transiently in adherent HEK 293T cells (CRL-3216, ATCC) using Invitrogen Lipofectamine 2000 Transfection Reagent (11668019, Thermo Fisher Scientific). Cells were cultured in ~15 mL of DMEM culture media (10569-044, Thermo Fisher Scientific) supplemented with 10% fetal bovine serum (35010CV, Corning) and 1% penicillin/streptomycin (15140122, ThermoFisher Scientific) in 75 cm<sup>2</sup> cell culture flasks (0030711122, Eppendorf) until reaching ~80% confluence. Lipofectamine 2000 (20  $\mu\text{g}/\text{flask}$ ) and plasmid DNA (8  $\mu\text{g}/\text{flask}$ ) were separately added to 0.5 mL OPTI-MEM media (31985-062, Thermo Fisher Scientific) and incubated for 10 min. Lipofectamine and DNA were then mixed and allowed to incubate for 30 min before addition to 15 mL DMEM. Spent media in the flasks was replaced with the media containing DNA and lipofectamine, and the cells were cultured for 3-4 d at 37 °C under 5% CO<sub>2</sub>. The media containing secreted antibody was harvested and centrifuged at 2500xg for 5 min to remove cells and cellular debris.

The secreted antibodies were purified via Protein A (20334, Thermo Fisher Scientific). Culture media was incubated with 1 mL (50% slurry) of Protein A agarose resin overnight at 4 °C on a rocking plate. The resin was collected by vacuum filtration in a 10 mL purification column (89898, Thermo Fisher Scientific), and the resin was washed with 100 mL of PBS. The antibodies were then incubated with 1.5 mL of 0.1 M glycine buffer (pH

2.5) for 15 min and eluted via centrifugation. The pH of the eluted protein solutions was adjusted to near-neutral by addition of one-tenth of the elution volume of 1 M  $K_2HPO_4$ , and the antibodies were buffer exchanged into PBS using Zeba Spin Desalting Columns (89891, Thermo Fisher Scientific). Protein concentrations were determined using micro-BCA assays or by measuring absorbance at 280 nm ( $\epsilon$ : 168,460 – 205,360  $M^{-1} cm^{-1}$ ) before use, and protein purity was confirmed by SDS-PAGE.

## **2.6 Antibody binding analysis**

### *2.6.1 Initial screening of antibodies*

Glucagon was diluted to 25  $\mu M$  in buffer (50 mM glycine, pH 2.5) for preparing the soluble peptide or in PBS for preparing the fibrillar peptide, and 100  $\mu L$  of sample was incubated overnight at 4 °C in Nunc MaxiSorp 96-well ELISA plates (439454, Thermo Fisher Scientific). All primary and secondary antibody binding steps were performed in PBS supplemented with 0.1% Tween20 and 1 g/L BSA (PBST-B) and the sample volumes were 100  $\mu L$ , unless otherwise specified. Wash steps between incubations were performed three times with 300  $\mu L$  of PBS. The antibodies were diluted to a concentration of 0.5 nM in PBST-B and incubated with immobilized glucagon for 1 h at room temperature. After washing, secondary antibody (Invitrogen Goat anti-Human IgG Fc HRP-conjugate, A18817, Thermo Fisher Scientific) was diluted 1:1000 (stock concentration of 0.5 mg/mL) into PBST-B and incubated for 1 h at room temperature. Antibody binding was detected by addition of 100  $\mu L$  of 1-Step Ultra-TMB ELISA Substrate Solution (34028, Thermo Fisher Scientific) to each well, and reactions were quenched with 2 M sulfuric acid (100  $\mu L$ ) after formation of the colored product. For all reported assays, reactions were quenched after 3-5 min. The absorbance of each well was measured at 450 nm using a Biotek Synergy Neo microplate reader. Reported signal ratios represent the ratio of the ELISA signal for plates coated with fibrillar glucagon to signal for plates coated with soluble glucagon at an equivalent concentration.

Binding curves for four of the most promising antibodies were generated using the following procedure. First, soluble or fibrillar glucagon was diluted to 2.5  $\mu M$  (50 mM glycine, pH 2.5), and 100  $\mu L$  of sample was incubated overnight at 4 °C in Nunc MaxiSorp 96-well ELISA plates. After washing, the antibodies were added to the wells at concentrations of 150, 50, 15, 5, 1.5, 0.5, 0.15, 0.05, 0.015, 0.005, and 0.0015 nM in PBST-B. Antibodies were incubated for 1 h at room temperature. The sequence specificity of the antibodies for glucagon fibrils was examined using human A $\beta$ 1-42,  $\alpha$ -synuclein, and islet amyloid polypeptide (IAPP) fibrils. The respective antigens were immobilized to the plates overnight at 4 °C at a concentration of 2.5  $\mu M$ . After washing, the antibodies were incubated at concentrations of 0.5 and 5 nM in PBST-B for 1 h at room temperature. Secondary antibody binding and substrate development/quenching were performed as previously described.

### *2.6.2 Screening assay conditions for optimal antibody sensitivity*

Three different types of ELISA plates and three primary antibody binding solutions were used to study the robustness of the ELISA assay. Soluble and fibrillar glucagon were separately immobilized (50 mM glycine, pH 2.5) for 2 h (room temperature) using a range of peptide concentrations (0.0005-25  $\mu M$ ) in MaxiSorp (439454,

Thermo Fisher Scientific), Medium Binding (655080, Greiner Bio-One), and High Binding (655081, Greiner Bio-One) 96-well ELISA plates. After washing, antibody (0.5 nM) was added for fibril detection.

The effect of solution conditions during the primary antibody binding step of the immunoassay was also investigated. Soluble and fibrillar glucagon were immobilized (2.5  $\mu$ M) in the wells of a MaxiSorp plate overnight at 4 °C. After washing, primary antibodies were incubated at a range of concentrations (0.5, 5, and 50 nM) with the immobilized peptides for 1 h at room temperature in i) PBS supplemented with 0.1% Tween20 and 1 g/L BSA (PBST-B), ii) PBS supplemented with 0.1% Tween20 and 100 g/L BSA, and iii) PBS supplemented with 0.1% Tween20, 1 g/L BSA, and 0.1% milk. Secondary antibody binding and substrate addition/quenching were performed as previously described.

### *2.6.3 Detection of glucagon fibrils in mixtures of soluble and fibrillar glucagon*

Mixtures of fibrillar and soluble glucagon containing a wide range of initial concentrations of fibril were prepared at a total glucagon concentration of 200  $\mu$ M (50 mM glycine, pH 2.5). The mixtures were incubated in Nunc MaxiSorp 96-well plates and allowed to bind for 2 h (room temperature). After washing, the primary antibodies (0.5 nM) were incubated for 1 h at room temperature (PBST-B). Secondary binding and substrate development/quenching were performed as previously described. For ThT detection of glucagon fibrils, mixtures were prepared at a total concentration of 245  $\mu$ M (50 mM glycine, pH 2.5) and incubated in microcentrifuge tubes for 2 h. ThT was added (final concentrations of 400, 40, or 4  $\mu$ M) while maintaining the final glucagon concentration at 200  $\mu$ M. After 5-10 min, 50  $\mu$ L of sample was added to black 384-well plates (Fisherbrand 384 Well Polystyrene Plates; 12566624, Thermo Fisher Scientific), and ThT fluorescence ( $\lambda_{ex}$ =444 nm,  $\lambda_{em}$ =482 nm) values were measured in a Biotek Synergy Neo microplate reader.

### *2.6.4 Optimization of ELISA microtiter plates by pre-treatment with globular proteins*

Nunc MaxiSorp plates were coated with four different globular proteins of varying isoelectric point [BSA (acidic), ovalbumin (acidic), lysozyme (basic), and avidin (basic)]. Proteins were dissolved at 1 g/L in PBS, filtered, and immobilized overnight at 4 °C. After washing, mixtures of soluble and fibrillar glucagon (total peptide concentration of 200  $\mu$ M) were incubated in the plates for 2 h at room temperature. Surface-immobilized fibrils were detected by incubation with primary antibody (0.5 nM) in PBST-B for 1 h at room temperature, and the rest of the detection process was performed as previously described.

### *2.6.5 Effect of glucagon concentration on ELISA sensitivity*

MaxiSorp plates were coated with 1 g/L BSA (PBS, filtered) overnight at 4 °C. Mixtures of soluble and fibrillar glucagon were prepared in 50 mM glycine (pH 2.5) at a total glucagon concentration of 200, 20 and 2  $\mu$ M. The mixtures were incubated in the plates for 2 h at room temperature, the plates were washed, and fibrils were detected using primary antibody (0.5 nM) in PBST-B, with secondary incubation and substrate addition/quenching performed as previously described.

### 3. RESULTS

#### 3.1 Identification of conformational antibodies specific for glucagon amyloid fibrils

Our first efforts toward selection of conformational antibodies against glucagon amyloid fibrils involved antigen assembly and characterization for subsequent use during antibody selection. Glucagon fibrils were assembled from soluble glucagon (1 g/L, 50 mM glycine, and pH 2.5) and recovered via ultracentrifugation. The properties of the resulting aggregates were studied using an amyloid-specific dye (ThT), intrinsic tryptophan fluorescence, and atomic force microscopy (AFM; Figure 1). The amyloid nature of the fibrils was confirmed by high ThT fluorescence (Figure 1a), a significant blue-shift in the intrinsic tryptophan fluorescence emission maxima relative to soluble glucagon (Figure 1b), and fibril-like morphology as revealed by AFM (Figure 1c).

Next, we sought to screen for antibodies with selective affinity for the fibrillar form of glucagon. The antibody library that was used for yeast surface display was prepared using the variable regions from 4D5 (Albanell and Baselga 1999) with diversification at 15 sites in heavy chain CDR3 (HCDR3). The DNA encoding the antibody library was fused to a yeast cell-surface protein (Aga2). Antibodies expressed on the surface of yeast were sorted via negative selections against magnetic beads coupled with soluble glucagon, while positive sorts were performed against beads coated with fibrillar glucagon.

Following eight rounds of iterative negative and positive sorting, the enriched antibody library was recovered, cloned as scFv-Fc antibodies, and sequenced. We identified 23 unique antibodies, which were subsequently expressed in HEK 293T and purified using immobilized protein A chromatography. Next, we examined the conformational specificity of the antibodies by immobilizing soluble and fibrillar glucagon (25  $\mu$ M) in 96-well ELISA microtiter plates (Figure 2). Binding of the antibodies was assessed at a relatively low concentration (0.5 nM). A majority of the 23 antibodies displayed high degrees of conformational specificity for glucagon fibrils relative to soluble peptide, while also displaying low levels of background binding to uncoated ELISA plates.

The conformational specificity of four of the most promising antibodies was evaluated in more detail by testing a range of primary antibody concentrations (Figure 3). Even at high antibody concentrations (>100 nM), we observed high conformational specificity, with concentrations between 0.5 and 5 nM providing the greatest discrimination between the soluble and fibrillar forms of glucagon. Notably, the four antibody variants performed similarly in this experiment, which led us to further assess their binding to other amyloid species (human A $\beta$ 1-42,  $\alpha$ -synuclein, and IAPP fibrils; Supporting Information Figure S1). Unexpectedly, we observed that the antibody variants recognized some of the non-glucagon fibrils. Relative to glucagon fibrils, the antibodies displayed increased binding to IAPP fibrils, reduced binding to A $\beta$ 1-42 fibrils, and little binding to  $\alpha$ -synuclein fibrils. It is unclear why the antibodies react with some amyloids and not others, and it is not possible to predict the antibody reactivity with other amyloidogenic polypeptides without further experimental analysis. Collectively, these results demonstrate that the antibodies we isolated recognize glucagon fibrils with high conformational specificity and amyloid fibrils of a subset of non-glucagon peptides.

We next sought to evaluate the impact of the ELISA plate type and assay conditions on the performance of our immunoassay. Considering that glucagon is a relatively small peptide and different types of ELISA plates are optimized for immobilization of distinct sizes, classes, and types of biomolecules, we sought to examine if any specific type(s) of ELISA plates offered improved assay sensitivity. However, we observed similar performance for three types of ELISA plates (Supporting Information Figure S2), suggesting that assay performance was weakly influenced by the type of microtiter plates that were used. We also evaluated the impact of the solution conditions employed during antibody binding on assay performance (Supporting Information Figure S3). Addition of high concentrations of BSA during antibody binding led to relatively small effects on assay performance. However, addition of 0.1% milk during primary antibody binding completely inhibited recognition of glucagon fibrils. These results indicate that the antibodies recognize glucagon amyloid fibrils via molecular interactions that can be blocked by the components in milk.

### **3.2 Optimization of ELISA detection of glucagon fibrils**

To mimic detection of low levels of endogenous glucagon amyloids in purified drug product, we next sought to test if our antibodies could detect low concentrations of glucagon fibrils in the presence of a large excess of soluble glucagon (Figure 4). Therefore, we prepared mixtures of fibrillar and soluble glucagon containing low initial concentrations of fibril (0-10 nM) at total glucagon concentrations of 200  $\mu$ M (~0.7 g/L). These mixtures were incubated in the ELISA plates for 2 h at room temperature. Encouragingly, wells incubated with glucagon samples initially containing  $\geq 1$  nM of fibril gave rise to detectable antibody binding signals. For comparison, fibril/soluble glucagon mixtures were prepared and incubated in microcentrifuge tubes for 2 h before analysis with the amyloid-specific fluorescent dye ThT (final glucagon concentration of 200  $\mu$ M after addition of ThT). Importantly, ThT fluorescence (above background) was only detected at initial glucagon fibril concentrations  $\geq \sim 10$  nM (Figure 4). These results demonstrate that our immunoassay is an order of magnitude more sensitive than a conventional amyloid detection assay. The concentration of ThT also impacted the sensitivity of glucagon amyloid detection, as we find concentrations of ThT  $> 40$   $\mu$ M display reduced sensitivity (Supporting Information Figure S4).

We reasoned that the sensitivity of our ELISA assay could be enhanced by using our antibodies as capture reagents in a sandwich ELISA format. However, our initial efforts at developing a sandwich ELISA revealed that glucagon fibrils efficiently immobilized even if the ELISA plates were first blocked with globular proteins (data not shown). This interesting result led us to explore whether the surface of the ELISA plates could be optimized for fibril capture by pretreatment with different globular proteins prior to incubation with glucagon (Figure 5). Four different globular proteins with varying isoelectric points (BSA, ovalbumin, lysozyme, and avidin) were used to treat the MaxiSorp plates prior to incubation with the mixtures of soluble and fibrillar glucagon. Relative to untreated plates, pretreatment with BSA and ovalbumin significantly improved assay sensitivity (~5-fold and



~2-fold increases in sensitivity, respectively; Figure 5). In contrast, pretreatment with lysozyme led to modest improvements and pretreatment with avidin decreased assay performance (Figure 5).

Finally, we evaluated the performance of our optimized assay as a function of glucagon concentration (Figure 6). BSA-treated plates were used for the immobilization of glucagon mixtures prepared at three different total glucagon concentrations (2, 20 and 200  $\mu$ M), and the assay signal was compared for data points collected at the same initial fibril concentrations. We find that 10-fold increases in total peptide concentration correspond to ~10-fold increases in assay sensitivity (Figure 6a). This result demonstrates that seeding of fibrillation during glucagon immobilization is more pronounced at higher glucagon concentrations, and that this factor plays an important role in enhancing assay sensitivity. We also analyzed the results in terms of the percentage of fibril initially present in the sample mixture (Figure 6b). These results demonstrate that our optimized assay is capable of detecting extremely low (~1 ppm) levels of glucagon fibrils.

#### 4. DISCUSSION

We have reported the discovery of a panel of conformational antibodies that recognize glucagon amyloids with high specificity, as well as the optimization of an ELISA for their use in detecting aggregates in purified glucagon product. Interestingly, our antibodies also cross-react with a subset of fibrils of other amyloidogenic peptides. While antibody sequence promiscuity would normally represent a concern during the development of a sensitive immunoassay, antibody recognition of different types of amyloids does not present an issue for detection of glucagon fibrillation in purified and formulated product. Rather, these results raise the intriguing possibility that our antibodies may recognize conserved amyloid structural motifs, such as  $\beta$ -sheets or an amyloid-specific arrangement of the peptide backbone. This would be consistent with previous identification of conformational antibodies that recognize a broad range of prefibrillar or fibrillar conformers formed by different amyloidogenic polypeptides (Hrcic et al. 2000; Isas et al. 2010; Kaye and Glabe 2006; Kaye et al. 2007; Kaye et al. 2003; O'Nuallain and Wetzel 2002; Wu et al. 2010). Interestingly, glucagon itself is known to form at least five distinct morphologies of amyloids that differ in their biophysical properties and ThT staining (De Jong et al. 2006; Gratzer et al. 1967; Pedersen 2010; Pedersen et al. 2006; Pedersen and Otzen 2008). Consequently, antibodies capable of recognizing different types of glucagon fibrils likely to form at formulation concentrations would provide a more comprehensive analysis of glucagon product quality. We are currently working to understand which type(s) of glucagon fibrils are recognized in our ELISA method.

We also observed a striking enhancement of ELISA sensitivity (~100-fold) when fibril is present in glucagon samples containing high concentrations of the soluble peptide. Using untreated MaxiSorp microtiter plates, the antibodies recognized purified, immobilized glucagon fibrils at concentrations  $\geq 100$  nM, but detected fibrillation in mixtures with soluble peptide at much lower concentrations (initial fibril concentrations as low as 1 nM). This finding suggests that extremely low concentrations of fibril are efficient at seeding fibrillation during short incubation times (2 h), even without agitation. It is possible that i) fibrils are immobilized and then are amplified

via seeding, ii) fibrils are amplified via seeding in solution and then immobilized, or iii) fibril seeding occurs both in solution and after immobilization. Regardless of the exact mechanism, it is likely that glucagon fibril seeding amplifies the detection sensitivity of our ELISA method.

Another contributing factor to the sensitivity of our assay is that glucagon fibrils were immobilized even when we first preblocked the ELISA plate with globular proteins. Notably, preblocking the plates with acidic proteins (BSA and ovalbumin, pIs of ~4.5-4.7) improved assay performance, while basic proteins (lysozyme and avidin, pIs > 10) had little or negative impact. The mechanism through which acidic proteins such as BSA enhance the ELISA signal remains unclear. BSA may improve immobilization of glucagon fibrils and/or reduce immobilization of soluble glucagon. It is notable that the glucagon samples were immobilized at pH 2.5, which is well below the isoelectric points of BSA (pI of ~4.7) and glucagon (pI of ~7.1). Therefore, electrostatic interactions do not appear to explain the mechanism by which BSA and ovalbumin improve the assay performance. Alternatively, non-electrostatic interactions – such as hydrophobic interactions - between the albumins and glucagon fibrils may promote glucagon fibril immobilization relative to soluble glucagon immobilization. Regardless of the exact mechanism, it is clear that albumins modify the microtiter plate surface in a manner that enhances detection sensitivity, and this finding may be valuable for improving the detection of other amyloid-forming proteins in related types of ELISAs.

Finally, it is important to consider the practical implications of using our ELISA method for detecting glucagon aggregation relative to the conventional method (ThT). Most previous studies using ThT to detect low levels of amyloid require agitation and long incubations (many hours) to enhance fibril seeding and amplification of pre-existing aggregates (Pedersen et al. 2006; Pedersen and Otzen 2008). The need for agitation over long times is likely linked to the well-known problems with poor reproducibility of ThT assays. Our approach requires relatively short incubation times (2 h) without agitation, which results in robust reproducibility. Our future work aims to improve antibody affinity in order to enhance the sensitivity of the assay for detection of endogenous aggregates of glucagon and related peptides without the need for agitation and aggregate amplification.

## **5. CONCLUSIONS**

Protein aggregation is a critical concern during the manufacture, formulation, and storage of a wide range of biopharmaceuticals. Therefore, it is particularly important to develop analytical methods and reagents for analysis of biopharmaceutical product quality in aggregation-prone products. We expect that our discovery of antibodies that recognize glucagon amyloid fibrils with high conformational specificity will improve the detection of aggregates using fast, simple and reproducible ELISA methods. Our assay is much more sensitive than conventional (ThT) methods and does not require agitation to amplify pre-existing aggregates. Importantly, we find that glucagon fibril detection can be enhanced by pretreating ELISA plates with globular proteins and that fibril seeding during antigen immobilization greatly improves assay sensitivity. We expect that additional future

research will enable even greater improvements in detection sensitivity and lead to unparalleled detection of peptide aggregates during the drug development process.

## **ACKNOWLEDGEMENTS**

We thank members of the Tessier lab for their helpful suggestions. This work was supported by Novo Nordisk, and the Albert M. Mattocks Chair (to P.M.T).


## **CONFLICTS OF INTEREST**

J.E.M., A.S., D.J.A., and L.S. are employees of Novo Nordisk. P.M.T. has received honorarium and consulting fees from Novo Nordisk.


## REFERENCES

- Albanell J, Baselga J. 1999. Trastuzumab, a humanized anti-HER2 monoclonal antibody, for the treatment of breast cancer. *Drugs Today (Barc)* 35(12):931-46.
- Bakhtiani PA, Caputo N, Castle JR, El Youssef J, Carroll JM, David LL, Roberts CT, Jr., Ward WK. 2015. A novel, stable, aqueous glucagon formulation using ferulic acid as an excipient. *J Diabetes Sci Technol* 9(1):17-23.
- Castle JR, Engle JM, El Youssef J, Massoud RG, Yuen KCJ, Kagan R, Ward WK. 2010. Novel use of glucagon in a closed-loop system for prevention of hypoglycemia in type 1 diabetes. *Diabetes care* 33(6):1282-1287.
- Chabenne JR, DiMarchi MA, Gelfanov VM, DiMarchi RD. 2010. Optimization of the native glucagon sequence for medicinal purposes. *J Diabetes Sci Technol* 4(6):1322-31.
- De Jong KL, Incedon B, Yip CM, DeFelippis MR. 2006. Amyloid fibrils of glucagon characterized by high-resolution atomic force microscopy. *Biophys J* 91(5):1905-14.
- Dobson CM. 1999. Protein misfolding, evolution and disease. *Trends Biochem Sci* 24(9):329-32.
- Dong M, Hovgaard MB, Xu S, Otzen DE, Besenbacher F. 2006. AFM study of glucagon fibrillation via oligomeric structures resulting in interwoven fibrils. *Nanotechnology* 17(16):4003-9.
- El-Khatib FH, Russell SJ, Nathan DM, Sutherland RG, Damiano ER. 2010. A bihormonal closed-loop artificial pancreas for type 1 diabetes. *Science translational medicine* 2(27):27ra27-27ra27.
- Falk R, Falk A, Dyson MR, Melidoni AN, Parthiban K, Young JL, Roake W, McCafferty J. 2012. Generation of anti-Notch antibodies and their application in blocking Notch signalling in neural stem cells. *Methods* 58(1):69-78.
- Ghodke S, Nielsen SB, Christiansen G, Hjuler HA, Flink J, Otzen D. 2012. Mapping out the multistage fibrillation of glucagon. *FEBS J* 279(5):752-65.
- Gratzer WB, Bailey E, Beaven GH. 1967. Conformational states of glucagon. *Biochem Biophys Res Commun* 28(6):914-9.
- Hall-Boyer K, Zaloga GP, Chernow B. 1984. Glucagon: hormone or therapeutic agent? *Crit Care Med* 12(7):584-9.
- Hovgaard MB, Dong M, Otzen DE, Besenbacher F. 2007. Quartz crystal microbalance studies of multilayer glucagon fibrillation at the solid-liquid interface. *Biophys J* 93(6):2162-9.
- Hrcic R, Wall J, Wolfenbarger DA, Murphy CL, Schell M, Weiss DT, Solomon A. 2000. Antibody-mediated resolution of light chain-associated amyloid deposits. *Am J Pathol* 157(4):1239-46.
- Isas JM, Luibl V, Johnson LV, Kaye R, Wetzel R, Glabe CG, Langen R, Chen J. 2010. Soluble and mature amyloid fibrils in drusen deposits. *Invest Ophthalmol Vis Sci* 51(3):1304-10.
- Kayed R, Glabe CG. 2006. Conformation-dependent anti-amyloid oligomer antibodies. *Methods Enzymol* 413:326-44.
- Kayed R, Head E, Sarsoza F, Saing T, Cotman CW, Necula M, Margol L, Wu J, Breydo L, Thompson JL and others. 2007. Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. *Mol Neurodegener* 2:18.
- Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG. 2003. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. *Science* 300(5618):486-9.
- O'Nuallain B, Wetzel R. 2002. Conformational Abs recognizing a generic amyloid fibril epitope. *Proceedings of the National Academy of Sciences* 99(3):1485-1490.
- Oliveira CL, Behrens MA, Pedersen JS, Erlacher K, Otzen D, Pedersen JS. 2009. A SAXS study of glucagon fibrillation. *J Mol Biol* 387(1):147-61.
- Onoue S, Ohshima K, Debari K, Koh K, Shioda S, Iwasa S, Kashimoto K, Yajima T. 2004. Mishandling of the therapeutic peptide glucagon generates cytotoxic amyloidogenic fibrils. *Pharm Res* 21(7):1274-83.
- Pedersen JS. 2010. The nature of amyloid-like glucagon fibrils. *J Diabetes Sci Technol* 4(6):1357-67.
- Pedersen JS, Dikov D, Flink JL, Hjuler HA, Christiansen G, Otzen DE. 2006. The changing face of glucagon fibrillation: structural polymorphism and conformational imprinting. *J Mol Biol* 355(3):501-23.
- Pedersen JS, Otzen DE. 2008. Amyloid-a state in many guises: survival of the fittest fibril fold. *Protein Sci* 17(1):2-10.


- Pohl R, Li M, Krasner A, De Souza E. 2015. Development of stable liquid glucagon formulations for use in artificial pancreas. *J Diabetes Sci Technol* 9(1):8-16.
- Russell SJ, El-Khatib FH, Nathan DM, Magyar KL, Jiang J, Damiano ER. 2012. Blood glucose control in type 1 diabetes with a bi-hormonal bionic endocrine pancreas. *Diabetes Care* 35(11):2148-55.
- Russell SJ, El-Khatib FH, Sinha M, Magyar KL, McKeon K, Goergen LG, Balliro C, Hillard MA, Nathan DM, Damiano ER. 2014. Outpatient glycemic control with a bionic pancreas in type 1 diabetes. *N Engl J Med* 371(4):313-325.
- Steiner SS, Li M, Hauser R, Pohl R. 2010. Stabilized glucagon formulation for bi-hormonal pump use. *J Diabetes Sci Technol* 4(6):1332-7.
- Unson CG. 2002. Molecular determinants of glucagon receptor signaling. *Biopolymers* 66(4):218-35.
- Wang W. 2005. Protein aggregation and its inhibition in biopharmaceutics. *Int J Pharm* 289(1-2):1-30.
- Ward WK, Massoud RG, Szybala CJ, Engle JM, El Youssef J, Carroll JM, Roberts CT, Jr., DiMarchi RD. 2010. In vitro and in vivo evaluation of native glucagon and glucagon analog (MAR-D28) during aging: lack of cytotoxicity and preservation of hyperglycemic effect. *J Diabetes Sci Technol* 4(6):1311-21.
- White JW, Saunders GF. 1986. Structure of the human glucagon gene. *Nucleic Acids Res* 14(12):4719-30.
- Wu JW, Breydo L, Isas JM, Lee J, Kuznetsov YG, Langen R, Glabe C. 2010. Fibrillar oligomers nucleate the oligomerization of monomeric amyloid beta but do not seed fibril formation. *J Biol Chem* 285(9):6071-9.



**FIGURE 1.** Glucagon fibril assembly and antigen characterization. Glucagon fibrils were assembled at a concentration of 1 g/L in 50 mM glycine (pH 2.5) using agitation (900 rpm) at 37 °C. The amyloid nature of the resulting peptide aggregates was evaluated using (a) Thioflavin T fluorescence (emission scans,  $\lambda_{ex}$  = 444 nm), (b) tryptophan (intrinsic) fluorescence (emission scans,  $\lambda_{ex}$  = 280 nm), and (c) atomic force microscopy. In (a) and (b), the experiments were performed three times (representative data shown), and (c) shows an AFM image from a typical fibril assembly with the scale bar displaying fibril height/depth.




**FIGURE 2.** Evaluation of the conformational specificity of a panel of glucagon antibodies. Soluble or fibrillar glucagon was immobilized overnight in Nunc MaxiSorp ELISA plates at a concentration of 25  $\mu$ M (4  $^{\circ}$ C), and the specificity of each antibody (0.5 nM) for fibrillar glucagon relative to soluble peptide was determined. The normalized binding of the antibodies to fibrillar glucagon relative to background and the normalized binding of the antibodies relative to soluble glucagon are reported. Error bars represent standard deviations.




**FIGURE 3.** Characterization of the concentration-dependent binding of glucagon antibodies. The specificity of antibodies for glucagon fibrils relative to soluble glucagon was evaluated using glucagon immobilized in MaxiSorp plates (2.5  $\mu$ M). The reported values are normalized ELISA signals. Average values for three independent experiments are reported, and the error bars are standard errors. The data are fit using three-parameter Hill equations.






**FIGURE 4.** Comparison of glucagon amyloid detection using conformational antibodies and an amyloid-specific fluorescent dye (ThT). Antibody detection was performed using mixtures of soluble and fibrillar glucagon prepared at a total glucagon concentration of 200  $\mu\text{M}$  and immobilized in ELISA plates for 2 h. ThT detection (4  $\mu\text{M}$  ThT) was performed for mixtures of soluble and fibrillar glucagon prepared at a total glucagon concentration of 245  $\mu\text{M}$ , incubated in microcentrifuge tubes for 2 h, and diluted to a final glucagon concentration of 200  $\mu\text{M}$ . For antibody detection, the values represent the mean for four independent experiments. For ThT detection, the values represent the mean for three independent experiments. The reported values for antibody and ThT detection of glucagon fibrils are normalized to the values obtained for soluble glucagon, and the error bars represent standard errors.


## Glucagon antibodies



**FIGURE 5.** Preblocking microtiter plates with globular proteins enhances ELISA sensitivity. The performance of antibody detection of glucagon fibrils was compared using control (untreated) ELISA plates (dashed lines) and plates preblocked with four different globular proteins (solid lines) prior to glucagon sample incubation. The reported values represent the mean for at least three independent experiments, and error bars are standard errors.




**FIGURE 6.** ELISA sensitivity is strongly dependent on glucagon concentration. Mixtures of soluble and fibrillar glucagon were prepared at 2, 20, and 200  $\mu\text{M}$  containing a range of initial fibril concentrations. The glucagon mixtures were incubated in ELISA plates pretreated with BSA for 2 h and detected using glucagon antibodies (0.5 nM). The normalized ELISA absorbance values are reported for samples containing glucagon fibrils relative to soluble glucagon (control). The results of the assay are reported as a function of the (a) initial fibril concentration and (b) initial percentage of fibril. Reported values represent the mean for at least four independent experiments, and the error bars are standard errors.



**FIGURE S1.** Glucagon antibodies cross-react with other amyloid-forming peptides. Sequence specificity of the glucagon antibodies was assessed using A $\beta$ 1-42,  $\alpha$ -synuclein, and IAPP fibrils. Antigens were immobilized overnight (4  $^\circ$ C) at 2.5  $\mu$ M using untreated MaxiSorp plates. Two different primary antibody concentrations were evaluated, namely: (a,b) 5 nM and (c,d) 0.5 nM. The data reported in (a) and (c) represent the binding of each antibody to the different antigens relative to its binding to glucagon fibrils. In (b) and (d), the raw absorbance values are reported, including signals without the addition of primary antibody. The reported values represent the mean for three independent experiments, and the error bars are the standard errors.


## Glucagon antibodies

● Clone 11 ● Clone 15 ● Clone 19




**FIGURE S2.** Sensitivity of ELISA method is weakly impacted by the type of ELISA microtiter plate. Soluble and fibrillar glucagon were separately immobilized in (a) Greiner “High Binding”, (b) Greiner “Medium Binding”, and (c) Nunc “MaxiSorp” ELISA plates for 2 h at room temperature, and then were detected using glucagon antibodies (0.5 nM). The reported values are normalized signals for antibody binding to glucagon fibrils relative to soluble peptide for two independent experiments. The error bars represent standard deviations.

## Glucagon antibodies



**FIGURE S3.** Impact of the solution environment on antibody recognition of glucagon fibrils. Soluble and fibrillar glucagon ( $2.5 \mu\text{M}$ ) were immobilized in MaxiSorp plates (overnight,  $4^\circ\text{C}$ ). Glucagon antibodies (0.5, 5, and 50 nM) were allowed to bind to glucagon fibrils for 1 h in (a) PBS supplemented with 0.1% Tween 20 and 1 g/L BSA, (b) PBS supplemented with 0.1% Tween 20 and 100 g/L BSA, and (c) PBS supplemented with 0.1% Tween 20, 1 g/L BSA, and 0.1% milk prior to secondary antibody incubation and substrate development. The mean values are for antibody binding to glucagon fibril relative to soluble peptide, and they were obtained from three independent experiments. The error bars are standard errors.



**FIGURE S4.** Impact of ThT concentration on its sensitivity for detecting glucagon fibrils. Mixtures of soluble and fibrillar glucagon were prepared at a total concentration of 245  $\mu\text{M}$ , and the final peptide concentration was 200  $\mu\text{M}$  after the addition of ThT. The soluble and fibrillar glucagon mixtures were incubated in microcentrifuge tubes for 2 h at room temperature prior to addition of ThT. ThT fluorescence was evaluated ( $\lambda_{ex}$  = 444 nm,  $\lambda_{em}$  = 482 nm) using black, 384-well plates. The data represent the mean values for three independent experiments, and the error bars are standard errors.